Table 1.
Clinical Variables of MDS Patients and Telomere Size
| Diagnosis | Chemotherapeutic Treatment | Age | Cytogenetic Markers | IPSS | BM Cellularity | Telomere/DNA/HS5 DNA |
|---|---|---|---|---|---|---|
| RA | Untreated | 69 | Normal | 0.5 | hyper | 1.2266 |
| RA | Untreated | 82 | Normal | 0.5 | normal | 0.6244 |
| RA | Untreated | 88 | Normal | 0.0 | normal | 0.7561 |
| RARS | ATG and etanercept | 59 | Normal | 0.5 | hyper | 0.8689 |
| RARS | Etanercept and 5-azacytidine | 61 | Normal | N/A | hyper | 0.9637 |
| RARS | Lenalidomide | 67 | Normal | N/A | hyper | 0.7773 |
| RARS | Untreated | 76 | Normal | 0.0 | normal | 0.9935 |
| RCMD-RS | Untreated | 60 | Normal | 0.5 | hyper | 0.9290 |
| RCMD | Thalidomide | 63 | t(2:11) | 1.0 | hyper | 1.1520 |
| RCMD | Untreated | 49 | Complex, del(7) | 1.5 | hypo | 1.4119 |
| RCMD | Untreated | 51 | Normal | 0.5 | normal | 1.1578 |
| RCMD | Untreated | 59 | Normal | 0.5 | normal | 1.0133 |
| RCMD | Etanercept | 67 | tri(8),del(7) | 1.0 | normal | 1.1715 |
| RAEB-1 | Filgastrim and epoetin beta | 67 | Normal | 2.0 | hyper | 0.9538 |
| RAEB-1 | Untreated | 78 | Complex | 2.5 | hyper | 0.9852 |
| RAEB-1 | Untreated | 78 | Normal | 1.0 | hyper | 1.2953 |
| RAEB-1 | Untreated | 84 | del7 | 2.5 | hypo | 0.7844 |
| RAEB-1 | Etanercept and 5-azacytidine | 63 | Normal | 0.0 | normal | 0.7584 |
| RAEB-1 | Etanercept and 5-azacytidine | 67 | Complex | 1.5 | normal | 0.6967 |
| RAEB-1 | Etanercept and 5-azacytidine | 71 | Complex, del(7) | 2.5 | normal | 1.3762 |
| RAEB-1 | Etanercept and 5-azacytidine | 74 | Normal | 2.0 | normal | 0.8742 |
| RAEB-2 | 7+3 | 44 | Normal | 0.5 | hyper | 0.7911 |
| RAEB-2 | 7+3 and 5-azacytidine | 61 | Normal | 2.5 | hyper | 0.9675 |
| RAEB-2 | Untreated | 63 | Complex, del(7) | 3.0 | hyper | 0.8900 |
| RAEB-2 | Untreated | 67 | Complex | 3.0 | hyper | 1.0004 |
| RAEB-2 | Untreated | 76 | t(6:9) | 2.5 | hyper | 0.6525 |
| RAEB-2 | Etanercept and 5-azacytidine | 80 | Normal | 1.0 | hyper | 0.7538 |
| RAEB-2 | Etanercept and 5-azacytidine | 73 | del(5q) | 1.0 | hypo | 0.9119 |
| RAEB-2 | Untreated | 55 | t(10:22) | 1.5 | normal | 0.9264 |
| RAEB-2 | 5-azacytidine, thalidomide | 58 | tri(21) | 0.5 | normal | 0.7469 |
| MDS - 5q(-) | Untreated | 62 | del(5q) | 0.0 | normal | 0.9332 |
| MDS-unclassified | Untreated | 75 | Normal | 0.0 | normal | 0.8211 |
| MDS sec | FLAM | 64 | Normal | N/A | hyper | 0.9402 |
| MDS sec | Untreated | 77 | add(11q) | 1.5 | hyper | 0.8824 |
| MDS sec | 7+3 | 56 | Normal | N/A | hypo | 1.4281 |
| MDS sec | Irradiation | 59 | del(13) | 0.5 | normal | 1.4933 |
| MDS sec | Clofarabine | 71 | tri(8),del(7) | N/A | normal | 1.0847 |
| CMML | Untreated | 77 | Normal | N/A | normal | 0.6641 |